Meet Dr Prathap Reddy, 92-year-old who built India's largest healthcare empire, owns 71 hospitals, 5000 pharmacy outlets still works daily, his net worth is Rs…
Meet Dr Prathap Reddy, 92-year-old who built India's largest healthcare empire, owns 71 hospitals, 5000 pharmacy outlets, his net worth is Rs...
At an age when most people slow down, 92-year-old Dr. Prathap C. Reddy is still going strong, showing no signs of stepping back. The man behind Apollo Hospitals starts his day at 10 in the morning and works until 5 in the evening and six days a week. His routine, filled with energy and commitment, would put even younger professionals to shame. Dr. Reddy is the trailblazer who introduced India's first corporate hospital i.e. Apollo Hospitals. His bold idea transformed the medical department by bringing top-quality healthcare within reach of millions. He dreamed of a time when Indians wouldn't have to go abroad for advanced medical treatment and he made that dream come true.
Hailing from Chennai, Dr. Reddy earned his MBBS from Stanley Medical College and later went to the U.S. to specialize in cardiology. Though he could have built a successful life there, a heartfelt letter from his father in the early 1970s changed everything. It urged him to return to India and serve his homeland. That one decision laid the foundation for a revolution in Indian healthcare. How the idea of Apollo Hospitals was born?
In 1979, the death of a patient in India caused by the lack of advanced medical facilities left a lasting impact on Dr. Prathap C. Reddy. That tragic moment became the spark that ignited a mission: to bring world-class healthcare to India. Dr. Reddy promised himself that no one should lose their life simply because quality treatment wasn't available close to home.
What began as a single hospital has grown into one of India's most trusted healthcare networks. Today, Apollo Hospitals operates 71 hospitals, over 5,000 pharmacies, nearly 300 primary care clinics, a widespread diagnostics network, and a growing digital health platform. It has become a lifeline for millions across the country, offering advanced care across various specialties.
Beyond healthcare, Apollo has a market capitalization of more than Rs. 70,000 crore, the company is both a medical and financial powerhouse. The Reddy family holds nearly a 30 per cent stake in the enterprise, highlighting their continued dedication to its vision and future. Dr. Reddy's net worth
According to Forbes, Dr. Reddy's personal net worth stands at approximately Rs. 26,560 crore. Yet, despite his enormous success, he remains deeply grounded. For him, the goal has never been wealth, it has always been service. His financial achievements are simply the outcome of a purpose-driven life.
Dr. Reddy's story is one of vision, compassion, and determination. In a past interview with Business Today , he said, 'Success should make us humble and inspire us to do more for the country.' Even at 92, he lives by those words.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
an hour ago
- India Today
Appendix cancer on the rise among US millennials, new study finds
From breast and colon to stomach and pancreatic cancers, doctors are now seeing more cases in people under the age of 50. A new study adds another surprising cancer to that list: appendix it remains extremely rare, appendix cancer is steadily increasing, especially among younger generations - millennials and Gen Z in the US, according to new research published in the Annals of Internal study, led by researchers at Vanderbilt University Medical Centre, found that the number of people diagnosed with a type of appendix cancer called appendiceal adenocarcinoma (AA) has spiked in recent decades. Using data from the National Cancer Institute's SEER program, a comprehensive US cancer registry, researchers tracked cases between 1975 and analysed trends by birth cohort and discovered a clear pattern: people born after 1945 showed rising rates of appendix cancer, with the sharpest increases among those born in 1980 and 1985. A study found that the number of people diagnosed with a type of appendix cancer has spiked in recent decades. () advertisementIn fact, rates tripled for the 1980 birth cohort and quadrupled for the 1985 group when compared to people born in 1945."This suggests that something has changed in the environment or lifestyle of newer generations that's contributing to this rise,' said lead researcher Dr. Andreana Holowatyji, assistant professor of hematology and oncology at IS THIS HAPPENING?Unlike more common cancers, the causes of appendix cancer remain appendix, a small pouch attached to the large intestine, was long overlooked and often lumped in with colon cancer. But as diagnostic tools and cancer registries improve, it's become easier to track this specific type of the number of appendectomies (surgical removal of the appendix) has stayed the same over the years, the researchers rules out the possibility that more cancers are simply being discovered because more surgeries are being researchers believe that lifestyle and environmental factors may be to blame. Rising rates of obesity and metabolic disorders among younger generations are a known risk factor for several cancers. But Holowatyji says it's probably not just one thing. The appendix, a small pouch attached to the large intestine, was long overlooked and often lumped in with colon cancer. () "It's likely a combination of influences, things like diet, chemicals in the environment, or even changes in the gut microbiome, that could be triggering changes in the body's cells and increasing the risk," she told IT MATTERS FOR INDIA'S YOUNG ADULTSThough the study was based on US data, the findings carry relevance globally, including for Indian millennials and Gen is also seeing an increase in young people diagnosed with cancers traditionally considered diseases of older inactive for long periods, high intake of processed diets, exposure to pollution, and lack of early screening all play a appendix cancer is still so rare, awareness among doctors and the public is low. This means symptoms, like unexplained bloating, changes in bowel habits, or appetite loss, can easily be dismissed as minor digestive authors of the study are calling for more research into the causes of appendix cancer, especially in younger populations, increased awareness not just among medical professionals but also among young adults themselves. advertisement
Business Standard
an hour ago
- Business Standard
AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge
AstraZeneca Pharma India declined 1.57% to Rs 9,878 after the company said its managing director (MD), Sanjeev Kumar Panchal has resigned from his position with effect from the close of business on 30 June 2025. Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board acknowledged his resignation and placed on record its appreciation for his contributions during his tenure. Following the recommendation of the nomination and remuneration committee, the board has approved the appointment of Praveen Rao Akkinepally as the new MD. He will take charge from 1 July 2025, for a term of three years. Akkinepally is a senior commercial leader with over two decades of experience across the US, global markets, and India, particularly in oncology and biopharmaceuticals. He has led several brand launches and driven global commercial strategies at AstraZeneca. His previous role as oncology business unit head for India saw significant growth in the companys market presence and a series of successful oncology product launches. Beyond his corporate achievements, he has contributed to healthcare policy through his work with the Federation of Indian Chambers of Commerce and Industrys cancer round tables. Akkinepally holds an MBA from the University of Michigans Ross School of Business and a masters in public health from Johns Hopkins University. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024.
New Indian Express
an hour ago
- New Indian Express
PG medicos launch stir over non-payment of stipend in Telangana
HYDERABAD: Postgraduate interns at Dr Patnam Mahender Reddy Institute of Medical Sciences (PMRIMS) in Chevella launched a strike on Monday, demanding the release of their long-pending stipends. For several months, students have been urging the college administration to clear the outstanding payments, ensure regular disbursal and revise the stipend amount to match those offered in government medical colleges as per Government Order (GO) 59. Frustrated by the administration's inaction, the students resorted to a protest. According to the agitating students, stipends for second-year postgraduates have been pending since September, while first-year students have not received payment for the past three months. They alleged that the college has been paying only Rs 10,000 per month since the first year — an amount they say is grossly insufficient to cover basic expenses. 'We have been requesting an increase in the stipend since our first year,' said Dr Mohammed Ismail, a second-year PG student, speaking to TNIE. 'Even though we managed with RS 10,000 initially, we demanded the amount be revised in line with GO 59. But there has been no response. On top of that, no one in the administration is taking responsibility. We are made to work long hours without fair compensation.'
